FNYS
SRPT icon

First New York Securities’s Sarepta Therapeutics SRPT Stock Holding History

First New York Securities’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-7,500
Closed -$191K – 463
2013
Q4 		$152K Buy
7,500
+7,000
+1,400% +$208K 0.09% 136
2013
Q3 		$24K Buy
+500
New +$19.3K 0.01% 310

Other funds holding SRPT

Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

First New York Securities's SRPT Position: Q1 2014 in Review

First New York Securities sold out of Sarepta Therapeutics (SRPT) in Q1 2014, closing a stake of 7,500 shares — an estimated $191K sold.

First New York Securities first reported a position in SRPT in Q3 2013 and held it in 2 quarters. The position peaked at $152K in Q4 2013. 114 funds tracked by Wall St. Rank hold SRPT as of Q1 2014.

  • First New York Securities reported no remaining Sarepta Therapeutics position as of Q1 2014 after selling out during the quarter.
  • First New York Securities sold 7,500 Sarepta Therapeutics shares in Q1 2014, an estimated $191K.
  • First New York Securities first reported a position in Sarepta Therapeutics in Q3 2013 and held it in 2 quarters.
  • First New York Securities's Sarepta Therapeutics position peaked at $152K in Q4 2013.
  • 114 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2014.

Based on First New York Securities's 13F filing for Q1 2014, filed 15 May 2014.